CML 2021: How to manage treatment failure in CML

A patient-based approach

The introduction of tyrosine kinase inhibitors has significantly improved the prognosis of chronic myeloid leukemia patients but many patients fail therapy either through development of resistance or intolerance and sometimes through multiple lines where patients have limited options.

Using a principally case-based approach, this programme will help clinicians to understand how best to decide on options following treatment failure to achieve the best outcome for their patients.

Join leaders in the treatment of chronic myeloid leukemia (CML) for a three-part series of workshops. Each session will accept a small number of delegates to participate in lively discussion and interactions with our hosting panel of clinical experts.

Together, you will review the treatments currently available to CML patients and probe new therapies on the horizon. Using scenario-based case studies, participants will be encouraged to contribute to the debate, pose questions and interact with live polls.

Meet the Expert: Session 1

First-line treatment, diagnosis, family planning and intolerance

Recorded: Wednesday 13th October 2021

The first in the series of Meet the Expert sessions aims to increase confidence in diagnosis and first-line treatment options for CML, including alternative therapies in cases of intolerance and drug resistance and possible treatment plans for family planning.

Prof. Susanne Saußele, MD

III. Med. Klinik, Medizinische Fakultät Mannheim, University of Heidelberg, Mannheim, Germany

Prof. Susanne Saußele is Head of the CML Excellence Center and chief resident of the policlinic at the III. Med. Klinik, Medizinische Fakultät Mannheim, University of Heidelberg, both in Mannheim, Germany. She studied medicine at the University of Heidelberg and specialized in Internal Medicine and Hematology/Oncology. In 2017, she was appointed as Professor of the University of Heidelberg.

Prof. Saußele is also a project leader in EUTOS (European Treatment and Outcome study of CML) and is a member of the E-MPN (European Network for MPN), ELN CML Working Party and Scientific Program Committee of EHA.

Faculty

Dr. Massimo Breccia
Dr. Elisabetta Abruzzese

Dr. Massimo Breccia, MD

Department of Translational and Precision Medicine, University of Rome, Rome, Italy

Dr. Massimo Breccia is a medical assistant at Sapienza University of Rome, Azienda Policlinico Umberto I, Head of DH unit. He has authored or co-authored over 450 papers in peer-reviewed journals with a focus on biological and clinical aspects of acute and chronic myeloid leukemias and myelodysplastic syndromes. He is a peer-reviewer for several journals, including Blood, The Lancet, The Lancet Hematology, Haematologica, British Journal of Haematology, and Cancer. Dr Breccia is also an editorial board member or associate editor of several journals including Frontiers in Oncology and Cancer.

He is a member of SIE, SIES, EHA and participates as PI and SI in several clinical trials for CML, AML, and MDS. He is co-chair of GIMEMA QoL Working Party and elected member of MPN GIMEMA Working Party.

Dr. Elisabetta Abruzzese, MD

Ospedale S.Eugenio, Università di Roma, Rome, Italy

Dr. Elisabetta Abruzzese is Director of the CML and Lymphoma Clinic at Ospedale S.Eugenio, ASL Roma2, Università di Roma, Tor Vergata, Rome, Italy. She is actively involved as Principal Investigator in multiple phase II and III studies of CML and lymphomas and was a co-founder for the Pregnancy and CML Treatment International Committee.Dr. Elisabetta Abruzzese is also a member of the Italian Society of Haematology, Italian Society of Experimental Haematology, American Society of Haematology, European LeukemiaNet and of the national board of the Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Working Party on CML.

Meet the Expert: Session 2

Second-line treatment and beyond

Recorded: Tuesday 26th October 2021

Session two in the Meet the Expert series will focus on practical management when treatment for CML fails and examination of the novel therapeutic options that are available for patients at this time.

Dr. Gianantonio Rosti, MD

IRCCS/SIRHHC Scientific Institute for Research, Meldola, Italy

Dr. Gianantonio Rosti is a Senior Scientist at the IRCCS/SIRHHC Scientific Institute for Research, Hospitalization and Health Care “Dino Amadori” – Meldola (FC), Italy. He studied Medicine and Surgery at the University of Bologna and was a Fellow at the John Hopkins University Hospital (Baltimore, USA).

Dr. Rosti is a scientific board member of the Italian Group for Adult Hematologic Malignancies Chronic Myeloid Leukemia Working Party [GIMEMA CML WP]), European Investigators on CML (EICML) and a member of the steering committee for the European Treatment and Outcome Study (EUTOS) registry. He is also a member of the ELN recommendation panel (2013 and 2020), the International CML Foundation, and of the scientific board of the Max Foundation. His activitie extends to the no-profit association AIL (Italian Association Against Leukemia), being board member of the Bologna’s regional headquarter in addition to being an author or co-author to more than 300 papers and meetings abstracts.

Faculty

Prof. Fausto Castagnetti

Prof. Fausto Castagnetti, MD, PhD

S.Orsola-Malpighi University Hospital, Bologna, Italy

Prof. Fausto Castagnetti is Professor of Haematology at the University of Bologna (Italy) and Head of the Clinical Research Group on Chronic Myeloid Leukaemia at S. Orsola-Malpighi University Hospital, Bologna. Prof. Castagnetti is also a member of the GIMEMA (Gruppo Italiano Malattie EMatologiche dell’Adulto) CML Working Party (WP) and “European Investigators on CML” Group, and is the Scientific Secretary of the National Board of the GIMEMA CML WP. He has been involved in the EUTOS Project, within the frame of the European LeukemiaNet.

Prof. Castagnetti has been an author or co-author of more than 130 scientific papers, 6 book chapters, more than 350 meeting abstracts. He is the principal investigator or co-investigator in several investigator-initiated and company-sponsored clinical trials, and he has active involvement in grant research projects.

Meet the Expert: Session 3

Blast crisis, clonal evolution and stem cell transplantation

Recorded: Wednesday 1^st December 2021

Our final Meet the Expert session will take a look at the role of clonal evolution in disease progression, treatment options if the blast phase is reached, and where stem cell transplantation should still be considered.

Prof. Jane F. Apperley, MD, FRCP, FRCPath, FMedSci

Imperial College London, UK

Prof. Jane Apperley is the Chair of Haemato-Oncology at Hammersmith Hospital, London, and up until 2021, the Clinical Director for Clinical Haematology at the Imperial College Healthcare NHS Trust, London, and the Chair of the Centre of Haematology at the Imperial College, London. Prof. Apperley’s research interests include the biology and management of CML, including the use of tyrosine kinase inhibitors, and the effects of hematological diseases and their treatment on fertility, pregnancy and foetal outcomes. She has been a member of the European LeukemiaNet (ELN) CML Working Party since 2004 and has been involved with the ELN Consensus Guidelines since the first recommendations in 2006, initially as the ‘expert’ in stem cell transplantation. Prof. Apperley will lead the next version of the guidelines, with a predicted publication date of 2023. She has also been a member of the UK National Cancer Research Institute CML study group for >20 years, and played a key role in the development of the current British Committee For Standards In Haematology guidelines. Prof. Apperley is on the Board of Directors of the iCMLf and in 2021 became the Chair of the EHA Scientific Working Group in CML.

Faculty

Prof. Dr. Thomas Ernst
Prof. Susanne Saußele

Prof. Dr. Thomas Ernst, MD

Universitätsklinikum Jena, Jena, Germany

Prof. Thomas Ernst is coordinator of the University Tumor Center (UTC) and consultant of the Department of Hematology and Medical Oncology at the Jena University Hospital, Jena, Germany.

He obtained his medical degree from the University of Heidelberg in 2004, Germany. After 3 years in Mannheim, Germany, in the working group of Prof. Hehlmann, he spent another 3 years as a postdoctoral researcher at the Wessex Regional Genetics Laboratory (Prof Nick Cross) in Salisbury, UK. He then joined the Department of Hematology and Oncology (Prof Hochhaus) at the Jena University Hospital, Germany, where he became a specialist in internal medicine and hematology/medical oncology. Since 2015 he is senior consultant of the department and leads the CML research and diagnostic group. In 2020, he was appointed as an Associate Professor.

Prof. Susanne Saußele, MD

III. Med. Klinik, Medizinische Fakultät Mannheim, University of Heidelberg, Mannheim, Germany

Funding

The content and faculty for this program have been independently developed and/or selected by Springer Healthcare. Novartis Pharmaceutical Corporation provided unconditional funding and as such had no involvement with, or influence on the content and selection of faculty. The content is not intended for use by healthcare professionals in the US. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Opinions expressed do not reflect the views of Springer Healthcare. Springer Healthcare assumes no responsibility for any injury or damage to persons or property arising out of, or related to, any use of the material or to any errors or omissions. Please consult the latest prescribing information from the manufacturer for any products mentioned in this material.

CML 2021: How to manage treatment failure in CML

A patient-based approach

Meet the Expert: Session 1

First-line treatment, diagnosis, family planning and intolerance

Prof. Susanne Saußele, MD

Faculty

Dr. Massimo Breccia, MD

Dr. Elisabetta Abruzzese, MD

Meet the Expert: Session 2

Second-line treatment and beyond

Dr. Gianantonio Rosti, MD

Faculty

Prof. Fausto Castagnetti, MD, PhD

Meet the Expert: Session 3

Blast crisis, clonal evolution and stem cell transplantation

Prof. Jane F. Apperley, MD, FRCP, FRCPath, FMedSci

Faculty

Prof. Dr. Thomas Ernst, MD

Prof. Susanne Saußele, MD

Funding

Registration

Login